Clinical Trials
37 trialsI-SPY
QuantumLeap Healthcare Collaborative
Fulvestrant With or Without Ganetespib in HR+ Breast Cancer
Dana-Farber Cancer Institute
EUDARIO
Universitaire Ziekenhuizen KU Leuven
Paclitaxel and Ganetespib in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Fox Chase Cancer Center
STA-9090 in Previously Treated Patients With Advanced Esophagogastric Cancer
Massachusetts General Hospital
Crizotinib and Ganetespib (STA-9090) in ALK Positive Lung Cancers
Memorial Sloan Kettering Cancer Center
MESO-02
University College, London
GANNET53: Ganetespib in Metastatic, p53-mutant, Platinum-resistant Ovarian Cancer
Medical University Innsbruck
Ganetespib in Combination With Paclitaxel, Carboplatin, and Radiation Therapy in Treating Patients With Stage II-III Esophageal Cancer
M.D. Anderson Cancer Center
SARC023: Ganetespib and Sirolimus in Patients With MPNST (Malignant Peripheral Nerve Sheath Tumors)
Sarcoma Alliance for Research through Collaboration
Study of Hsp90 Inhibitor, STA-9090 for Relapsed or Refractory Small Cell Lung Cancer
Dana-Farber Cancer Institute
STA-9090(Ganetespib) in Metastatic Ocular Melanoma
Dana-Farber Cancer Institute
Hsp90 Inhibitor STA-9090 in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer Previously Treated With Docetaxel-Based Chemotherapy
Barbara Ann Karmanos Cancer Institute
Ganetespib, Paclitaxel, Trastuzumab and Pertuzumab for Metastatic Human Epidermal Growth Factor Receptor 2 Positive Breast Cancer
Memorial Sloan Kettering Cancer Center
STA-9090 in Patients With Advanced Hepatocellular Cancer
Massachusetts General Hospital
A Phase I/II Study of Ganetespib in Combination With Doxorubicin
Georgetown University
Ganetespib and Ziv-Aflibercept in Refractory Gastrointestinal Carcinomas, Non-Squamous Non-Small Cell Lung Carcinomas, Urothelial Carcinomas, and Sarcomas
National Institutes of Health Clinical Center (CC)
STA-9090(Ganetespib) in Patients With Unresectable Stage III or Stage IV Melanoma
Dana-Farber Cancer Institute
Ganetespib Window of Opportunity Study in Head and Neck Cancers
Emory University
Galaxy 2
Synta Pharmaceuticals Corp.
A Pilot Preoperative Trial of Ganetespib With Paclitaxel for Triple-Negative Breast Cancer
University of Chicago
A Study Evaluating STA-9090 in Patients With Metastatic and/or Unresectable Gastrointestinal Stromal Tumor (GIST)
Synta Pharmaceuticals Corp.
Phase I Trial of Ganetespib, Capecitabine, and Radiation in Rectal Cancer
Emory University
Clinical and Translational Study of STA-9090
Memorial Sloan Kettering Cancer Center
Open-label Study of STA-9090 for Patients With Metastatic Breast Cancer
Memorial Sloan Kettering Cancer Center
Enchant
Synta Pharmaceuticals Corp.
A Phase I Study of Ganetespib +/- Bortezomib in Patients With Relapsed and/or Refractory Multiple Myeloma
Emory University
STA-9090 in Castration-Resistant Prostate Cancer With Assessment of Androgen Receptor Pathway Signaling
Dana-Farber Cancer Institute
CHIARA
Synta Pharmaceuticals Corp.
A Study of the HSP90 Inhibitor, STA-9090 in Subjects With Stage IIIB or IV Non-Small Cell Lung Cancer (NSCLC)
Synta Pharmaceuticals Corp.
A Dose Escalation Study of STA-9090 and Docetaxel in Patients With Solid Tumors
Synta Pharmaceuticals Corp.
Study of STA-9090, Administered Once-Weekly in Patients With Solid Tumors
Synta Pharmaceuticals Corp.
Study of STA-9090, Administered Twice-Weekly in Patients With Solid Tumors
Synta Pharmaceuticals Corp.
STA-9090 for Treatment of AML, CML, MDS and Myeloproliferative Disorders
Synta Pharmaceuticals Corp.
A Phase 1 Study of the HSP90 Inhibitor, STA-9090 in Subjects With Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia and Blast-phase Chronic Myelogenous Leukemia
Synta Pharmaceuticals Corp.
PhII Study STA-9090 as Second or Third-Line Therapy for Metastatic Pancreas Cancer
Vanderbilt-Ingram Cancer Center
AML18 Pilot
Cardiff University